3-Hydroxy-5-Methoxybiphenyl-3-carboxylic acid
|
- $215 - $675
- Product name: 3-Hydroxy-5-Methoxybiphenyl-3-carboxylic acid
- CAS: 1215205-51-8
- MF: C14H12O4
- MW: 244.24
- EINECS:
- MDL Number:MFCD15143534
- Synonyms:3-Hydroxy-5-Methoxybiphenyl-3-carboxylic acid
4 prices
Selected condition:
Brand
- Crysdot
- TRC
Package
- 100mg
- 500mg
- 1g
- ManufacturerCrysdot
- Product numberCD12171959
- Product description3'-Hydroxy-5'-methoxybiphenyl-3-carboxylicacid 95+%
- Packaging1g
- Price$330
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD12171959
- Product description3'-Hydroxy-5'-methoxybiphenyl-3-carboxylic acid 95+%
- Packaging1g
- Price$330
- Updated2026-05-27
- Buy
- ManufacturerTRC
- Product numberH972733
- Product description3''-Hydroxy-5''-methoxybiphenyl-3-carboxylicacid
- Packaging500mg
- Price$675
- Updated2021-12-16
- Buy
- ManufacturerTRC
- Product numberH972733
- Product description3''-Hydroxy-5''-methoxybiphenyl-3-carboxylicacid
- Packaging100mg
- Price$215
- Updated2021-12-16
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| Crysdot | CD12171959 | 3'-Hydroxy-5'-methoxybiphenyl-3-carboxylicacid 95+% | 1g | $330 | 2021-12-16 | Buy |
| Crysdot | CD12171959 | 3'-Hydroxy-5'-methoxybiphenyl-3-carboxylic acid 95+% | 1g | $330 | 2026-05-27 | Buy |
| TRC | H972733 | 3''-Hydroxy-5''-methoxybiphenyl-3-carboxylicacid | 500mg | $675 | 2021-12-16 | Buy |
| TRC | H972733 | 3''-Hydroxy-5''-methoxybiphenyl-3-carboxylicacid | 100mg | $215 | 2021-12-16 | Buy |
Properties
Boiling point :501.4±45.0 °C(Predicted)
Density :1.287±0.06 g/cm3(Predicted)
pka :4.04±0.10(Predicted)
Density :1.287±0.06 g/cm3(Predicted)
pka :4.04±0.10(Predicted)
Safety Information
| Symbol(GHS): |
|
|||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal word: | Warning | |||||||||||||||||||||||||||||||||||
| Hazard statements: |
|
|||||||||||||||||||||||||||||||||||
| Precautionary statements: |
|




